UK Markets close in 8 hrs 9 mins

Merus N.V. (MRUS)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
14.97-0.20 (-1.32%)
At close: 04:00PM EST
15.71 +0.74 (+4.94%)
After hours: 07:39PM EST
Full screen
Trade prices are not sourced from all markets
Previous close15.17
Bid0.00 x 800
Ask0.00 x 900
Day's range14.51 - 15.01
52-week range12.03 - 33.09
Avg. volume338,920
Market cap638.794M
Beta (5Y monthly)0.94
PE ratio (TTM)N/A
EPS (TTM)-2.92
Earnings date27 Feb 2023 - 03 Mar 2023
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est42.30
  • Globe Newswire

    Merus to Participate in a Fireside Chat at the Stifel 2022 Healthcare Conference

    UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a fireside chat at the Stifel 2022 Healthcare Conference on Wednesday, November 16, 2022 at 1:50 p.m. ET. The webcast of the presentation will be contemporaneous

  • Simply Wall St.

    Merus Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag

    Merus ( NASDAQ:MRUS ) Third Quarter 2022 Results Key Financial Results Revenue: US$6.58m (down 52% from 3Q 2021). Net...

  • Zacks

    Merus N.V. (MRUS) Reports Q3 Loss, Misses Revenue Estimates

    Merus N.V. (MRUS) delivered earnings and revenue surprises of 11.67% and 38.84%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?